| Cover Page - shares | 3 Months Ended | |
| Mar. 31, 2024 | May 03, 2024 |
| Entity Information [Line Items] | | |
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Document Period End Date | Mar. 31, 2024 | |
| Document Fiscal Year Focus | 2024 | |
| Document Fiscal Period Focus | Q1 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Registrant Name | VOR BIOPHARMA INC. | |
| Entity Central Index Key | 0001817229 | |
| Entity File Number | 001-39979 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Tax Identification Number | 81-1591163 | |
| Entity Address, Address Line One | 100 Cambridgepark Drive | |
| Entity Address, Address Line Two | Suite 101 | |
| Entity Address, City or Town | Cambridge | |
| Entity Address, State or Province | MA | |
| Entity Address, Postal Zip Code | 02140 | |
| City Area Code | 617 | |
| Local Phone Number | 655-6580 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Entity Ex Transition Period | false | |
| Entity Common Stock, Shares Outstanding | | 68,259,602 |
| Entity Shell Company | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
| Trading Symbol | VOR | |
| Security Exchange Name | NASDAQ | |
| Amendment Description | This Amendment No. 1 on Form 10-Q/A (this “Amendment”) amends the Quarterly Report on Form 10-Q of Vor Biopharma Inc. (the “Company”) for the quarterly period ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024 (the “Original Filing”). This Amendment is being filed to amend and restate Part II, “Item 5. Other Information” by disclosing a Rule 10b5-1 trading arrangement entered into by our Chief Medical Officer on March 4, 2024, which was inadvertently omitted from the disclosure included in the Original Filing. In addition, as required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as an exhibit to this Amendment, under Item 6 hereof, pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, and such disclosure is not otherwise required to be amended given the nature of the reason for this Amendment, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002), as no financial statements are being filed with this Amendment. Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in the Original Filing or reflect any events that have occurred after the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time such Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC. | |
